Tirzepatide is a drug that promises to combat one of the most common
chronic illnesses in the world: type 2 diabetes. This condition develops
over time and is most commonly diagnosed in elderly patients. The hormone
insulin, produced by the pancreas, allows blood sugar to be processed by
our cells.In people with insulin resistance, the blood sugar can not be
efficiently taken in, which prompts the pancreas to produce more insulin.
This can be caused by many different outside factors in the form of
repeated unhealthy behaviors. Eventually, the amount of insulin needed for
glucose regulation can not be produced anymore, leading to the development
of type 2 diabetes.
chronic illnesses in the world: type 2 diabetes. This condition develops
over time and is most commonly diagnosed in elderly patients. The hormone
insulin, produced by the pancreas, allows blood sugar to be processed by
our cells.In people with insulin resistance, the blood sugar can not be
efficiently taken in, which prompts the pancreas to produce more insulin.
This can be caused by many different outside factors in the form of
repeated unhealthy behaviors. Eventually, the amount of insulin needed for
glucose regulation can not be produced anymore, leading to the development
of type 2 diabetes.
The new drug Tirzepatide is a dual glucose-dependent insulinotropic
polypeptide (GIP) and GLP-1 receptor antagonist, meaning it directly
activates the GIP and GLP-1 receptors in the body. These receptors increase
insulin production and thereby help reduce excess blood sugar.
Additionally, this delays stomach emptying, making it a potentially useful
drug against obesity – which often correlates with type 2 diabetes.
An estimate of around 10% of the world population suffer from diabetes.
